PT
This biotechnology company develops novel therapeutics targeting neurodegenerative and refractory inflammatory diseases through next-generation protein degradation technology. By focusing on these areas, the company aims to facilitate the advancement of drugs for conditions with significant unmet medical needs.
Updated 3 months ago
Funding
$15.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- This biotechnology company develops novel therapeutics targeting neurodegenerative and refractory inflammatory diseases through next-generation protein degradation technology. By focusing on these areas, the company aims to facilitate the advancement of drugs for conditions with significant unmet medical needs.